{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:19:15Z","timestamp":1787951955312,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijgc.2025.102772","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:11:00Z","timestamp":1761930660000},"page":"102772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of patients with metastatic squamous cell carcinoma of the vulva"],"prefix":"10.1016","volume":"36","author":[{"given":"Christian","family":"Dagher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawar A.","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Robert L.","family":"Giuntoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-1566","authenticated-orcid":false,"given":"Emily M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Nasioudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijgc.2025.102772_bib1","article-title":"Incidence trends ofvulvar cancer in the United States: a 20-year population-based study. Cancer rep","volume":"7","author":"Mousavi","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102772_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-077960","article-title":"Influence of stage and age on survival of patients with vulvar cancer in Germany: a retrospective study","volume":"14","author":"Mack","year":"2024","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102772_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ygyno.2014.12.013","article-title":"Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: time to reconsider the FIGO staging system?","volume":"136","author":"Thaker","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102772_bib4","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1245\/s10434-021-09744-y","article-title":"Role of pelvic lymph node resection in vulvar squamous cell cancer: a subset analysis of the AGO-CaRE-1 study","volume":"28","author":"Woelber","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102772_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/cancers17020186","article-title":"Management of patients with vulvar cancers: a systematic comparison of international guidelines (NCCN-ASCO-ESGO-BGCS-IGCS-FIGO-French guidelines-RCOG)","volume":"17","author":"Restaino","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102772_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ijgo.13880","article-title":"FIGO staging for carcinoma of the vulva: 2021 revision","volume":"155","author":"Olawaiye","year":"2021","journal-title":"Int J Gynecol Obstet"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102772_bib7","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/ijgc-2024-005677","article-title":"Secondary databases in gynecologic cancer research","volume":"34","author":"Hicks-Courant","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102772_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0090-8258(86)90138-1","article-title":"Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study","volume":"23","author":"Thigpen","year":"1986","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102772_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000259259","article-title":"Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma","volume":"77","author":"Cormio","year":"2009","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102772_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/IGC.0b013e31824b4058","article-title":"Weekly paclitaxel\/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer","volume":"22","author":"Han","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102772_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.humpath.2014.01.015","article-title":"EGFR expression in vulvar cancer: clinical implications and tumor heterogeneity","volume":"45","author":"de Melo Maia","year":"2014","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102772_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/jcp-2010-079806","article-title":"EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome","volume":"65","author":"Woelber","year":"2012","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102772_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2012.06.028","article-title":"Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva","volume":"127","author":"Horowitz","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102772_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000543554","article-title":"Trop2 expression in correlation to the molecular subtype in vulvar squamous cell carcinomas","volume":"92","author":"H\u00f6hn","year":"2025","journal-title":"Pathobiology"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102772_bib15","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1007\/s00432-023-04761-8","article-title":"TROP-2 is widely expressed in vulvar squamous cell carcinoma and represents a potential new therapeutic target","volume":"149","author":"Condic","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102772_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ygyno.2025.03.049","article-title":"Trop2-expression in primary vulvar squamous cell carcinoma","volume":"196","author":"Stuebs","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102772_bib17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00428-020-02759-y","article-title":"Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma","volume":"477","author":"Cocks","year":"2020","journal-title":"Virchows Arch"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102772_bib18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/his.15112","article-title":"PD-L1 expression in vulvar cancer: a systematic review and meta-analysis","volume":"84","author":"Baandrup","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.ijgc.2025.102772_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2025.01.001","article-title":"PD-L1-Expression in primary and recurrent vulvar squamous cell cancer","volume":"193","author":"Stuebs","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102772_bib20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102772_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2022.01.029","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Shapira-Frommer","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102772_bib22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102772_bib23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1078-0432.CCR-24-1957","article-title":"A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG S1609: vulvar cancers","volume":"31","author":"Chae","year":"2025","journal-title":"Clin Cancer Res."},{"issue":"6","key":"10.1016\/j.ijgc.2025.102772_bib24","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ijc.31139","article-title":"Does HPV status influence survival after vulvar cancer?","volume":"142","author":"Rasmussen","year":"2018","journal-title":"Int J Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25018948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25018948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:38:12Z","timestamp":1787949492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25018948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1048891X25018948"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102772","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of patients with metastatic squamous cell carcinoma of the vulva","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"102772"}}